 Zynerba Pharmaceuticals Inc NASDAQ: ZYNE presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder ASD over a longer-term, 38-week treatment period. Zygel is cannabidiol formulated in a transdermal gel. 